MedTrace Logo

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

NCT01478737 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-01-30

No results posted yet for this study

Summary

To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Intravitreal dexamethasone implant

Intravitreal Ozurdex after vitrectomy

PROCEDURE

Vitrectomy

Vitrectomy only

Sponsors & Collaborators

  • Anders Kvanta

    lead OTHER

Principal Investigators

  • Anders Kvanta, PhD · St. Erik Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01478737 on ClinicalTrials.gov